1. Adjuvant therapy in colon cancer: less is more. Issue 4 (April 2018) Authors: Ilson, David H Journal: Lancet oncology Issue: Volume 19:Issue 4(2018) Page Start: 442 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Advances in Esophageal and Gastric Cancers, An Issue of Surgical Oncology Clinics of North America. (2017) Authors: Ilson, David H Record Type: Book Extent: 1 online resource View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Emerging evidence for VEGF and immune checkpoint inhibition in oesophagogastric cancer. (March 2022) Authors: Ilson, David H Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 3(2022) Page Start: 200 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Emerging mAbs for the treatment of esophagogastric cancer. (March 2015) Authors: Ku, Geoffrey Y; Ilson, David H Journal: Expert opinion on emerging drugs Issue: Volume 20:Number 1(2015:Mar.) Page Start: 63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Emerging tyrosine kinase inhibitors for esophageal cancer. (June 2013) Authors: Ku, Geoffrey Y; Ilson, David H Journal: Expert opinion on emerging drugs Issue: Volume 18:Number 2(2013:Jun.) Page Start: 219 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Issue 6 (June 2020) Authors: Janjigian, Yelena Y; Maron, Steven B; Chatila, Walid K; Millang, Brittanie; Chavan, Shweta S; Alterman, Carly; Chou, Joanne F; Segal, Michal F; Simmons, Marc Z; Momtaz, Parisa; Shcherba, Marina; Ku, Geoffrey Y; Zervoudakis, Alice; Won, Elizabeth S; Kelsen, David P; Ilson, David H; Nagy, Rebecca J... Journal: Lancet oncology Issue: Volume 21:Issue 6(2020) Page Start: 821 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Hypothermic Intraperitoneal Chemotherapy for Gastrointestinal Malignancies—A Relic of the Past or Useful Tool for Today?. Issue 2 (2019) Authors: Greally, Megan; Ilson, David H Journal: Oncology & hematology review Issue: Volume 15:Issue 2(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. (19th February 2019) Authors: Bang, Yung-Jue; Van Cutsem, Eric; Fuchs, Charles S; Ohtsu, Atsushi; Tabernero, Josep; Ilson, David H; Hyung, Woo Jin; Strong, Vivian E; Goetze, Thorsten Oliver; Yoshikawa, Takaki; Tang, Laura H; Hwang, Peggy May Tan; Webb, Nancy; Adelberg, David; Shitara, Kohei Journal: Future oncology Issue: Volume 15:Number 9(2019) Page Start: 943 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Issue 3 (March 2019) Authors: Luft, Alexander V.; Karaseva, Nina A.; Kowalyszyn, Rubén Dario; Hernandez, Carlos Alberto; Csoszi, Tibor; De Vita, Ferdinando; Pfeiffer, Per; Sugimoto, Naotoshi; Kocsis, Judit; Csilla, Andràs; Bodoky, Gyorgy; Garnica Jaliffe, Georgina; Protsenko, Svetlana; Madi, Ayman; Wojcik, Elzbieta; Brenner, ... Journal: Lancet oncology Issue: Volume 20:Issue 3(2019) Page Start: 420 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 11 (November 2017) Authors: Catenacci, Daniel V T; Tebbutt, Niall C; Davidenko, Irina; Murad, André M; Al-Batran, Salah-Eddin; Ilson, David H; Tjulandin, Sergei; Gotovkin, Evengy; Karaszewska, Boguslawa; Bondarenko, Igor; Tejani, Mohamedtaki A; Udrea, Anghel A; Tehfe, Mustapha; De Vita, Ferdinando; Turkington, Cheryl; Tang,... Journal: Lancet oncology Issue: Volume 18:Issue 11(2017:Nov.) Page Start: 1467 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗